U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  New England Journal of Medicine

• Publication date

  2013-07-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1209165PMID 23841730PMCID PMC4877190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children.

  2013cited by this paper
• Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

  2013cited by this paper
• Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003-2009.

  2012cited by this paper
• Prevention of pneumococcal infection with vaccines: an evolving story.

  2012cited by this paper
• Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?

  2012cited by this paper
• Pneumococcal Carriage and Antibiotic Resistance in Young Children Before 13-valent Conjugate Vaccine

  2012cited by this paper
• Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia

  2012cited by this paper
• Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.

  2011cited by this paper
• Impact of Pneumococcal Conjugate Vaccination of Infants on Pneumonia and Influenza Hospitalization and Mortality in All Age Groups in the United States

  2011cited by this paper
• Diagnostic tests for agents of community-acquired pneumonia.

  2011cited by this paper
• Serotype replacement in disease after pneumococcal vaccination.

  2011cited by this paper
• Reduction in Hospitalizations for Pneumonia Associated With the Introduction of a Pneumococcal Conjugate Vaccination Schedule Without a Booster Dose in Australia

  2010cited by this paper
• Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997–2008

  2010cited by this paper
• Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States.

  2010cited by this paper
• Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization

  2010cited by this paper
• Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

  2010cited by this paper
• Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2009cited by this paper
• Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young Children

  2009cited by this paper
• Pneumococcal vaccine and the dance of the veils: revealing pneumonia burden in Asia.

  2009cited by this paper
• Influenza vaccination coverage among children aged 6 months--18 years - eight immunization information system sentinel sites, United States, 2008-09 influenza season.

  2009cited by this paper
• Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings.

  2009cited by this paper
• Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006.

  2009cited by this paper
• Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States.

  2007cited by this paper
• Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

  2007cited by this paper
• Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

  2007cited by this paper
• Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease.

  2006cited by this paper
• Effectiveness of Heptavalent Pneumococcal Conjugate Vaccine in Children Younger Than 5 Years of Age for Prevention of Pneumonia: Updated Analysis Using World Health Organization Standardized Interpretation of Chest Radiographs

  2006cited by this paper
• Nasopharyngeal colonization: a target for pneumococcal vaccination

  2006cited by this paper
• National Impact of Universal Childhood Immunization With Pneumococcal Conjugate Vaccine on Outpatient Medical Care Visits in the United States

  2006cited by this paper
• Increased prevalence of pediatric pneumococcal serotypes in elderly adults.

  2005cited by this paper
• Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002.

  2005cited by this paper
• Seven Valent Pneumococcal Conjugate Vaccine Immunization in Two Boston Communities: Changes in Serotypes and Antimicrobial Susceptibility Among Streptococcus pneumoniae Isolates

  2004cited by this paper
• Population-Based Impact of Pneumococcal Conjugate Vaccine in Young Children

  2004cited by this paper
• The New England Journal of Medicine における被訂正論文のインパクト

  2004cited by this paper
• Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

  2003cited by this paper
• Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

  2003cited by this paper
• Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance.

  2001cited by this paper

• Examining the role of IgA in a persistent model of Staphylococcus aureus colonization

  2026cites this paper
• Amoxicillin vs. ceftriaxone to treat pneumonia caused by amoxicillin-non-susceptible Streptococcus pneumoniae

  2025cites this paper
• Analysis of common respiratory pathogens in children aged 0–5 years with community-acquired pneumonia

  2025cites this paper
• Integrating DNA and RNA sequencing for enhanced pathogen detection in respiratory infections

  2025cites this paper
• Variations in Length of Stay and Cost of Pediatric Pneumonia Hospitalizations According to Patient and Institutional Factors.

  2025cites this paper
• Overvågning og forebyggelse af pneumokoksygdom – kan vi gøre det bedre?

  2025cites this paper
• Rationalizing recommendations for influenza and COVID-19 vaccines.

  2025cites this paper
• Rationale and design of the Pneumococcal Pneumonia Epidemiology, Urine Serotyping and Mental Outcomes (PNEUMO) study Europe

  2025cites this paper
• Pediatric Pulmonology

  2025cites this paper
• Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children

  2025cites this paper
• Effect of the Ten-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease and Pneumonia in Infants Younger Than Ten Weeks of Age in Southern Mozambique: A Population-based Prospective Surveillance Study

  2025cites this paper
• Vaccination against COVID-19 among healthcare workers as a cocoon strategy for people living with HIV

  2024cites this paper
• The Association of the MeMed BV Test With Radiographic Pneumonia in Children.

  2024cites this paper
• Vaccinations in older adults: Optimization, strategies, and latest guidelines

  2024cites this paper
• Drugs targeting CMPK2 inhibit pyroptosis to alleviate severe pneumonia caused by multiple respiratory viruses

  2024cites this paper
• Association between celiac disease and pneumococcal infections in hospitalized pediatric patients in the United States.

  2024cites this paper
• Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations after four years of its introduction into the Polish National Immunisation Programme: Follow-up study.

  2024cites this paper
• Respiratory syncytial virus infections in adults: a narrative review.

  2024cites this paper
• Comparison between metagenomic next-generation sequencing in bronchoalveolar lavage fluid and blood for the diagnostic performance of respiratory tract infection: a meta-analysis

  2024cites this paper
• The epidemiology and healthcare costs of community-acquired pneumonia in Ontario, Canada: a population-based cohort study

  2023cites this paper
• Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP

  2023cites this paper
• Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.

  2023cites this paper
• Reductions in Childhood Pneumonia Mortality After Vaccination in the United States

  2023cites this paper
• Evaluation of the direct and indirect impact on pneumonia hospitalization after almost a decade of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Brazil

  2023cites this paper
• Pneumonia among under – five children in Ethiopia: a retrospective analysis from an urban hospital

  2023cites this paper
• Impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia hospitalisations in Mongolia: a time series analysis

  2023cites this paper
• Febrile Children with Pneumonia Have Higher Nasopharyngeal Bacterial Load Than Other Children with Fever

  2023cites this paper
• Management of pneumonia in the critically ill.

  2023cites this paper
• Pneumococcal Disease: Global Disease Prevention Strategies with a Focus on the Challenges in Iraq

  2023cites this paper
• Association between nasopharyngeal colonization with multiple pneumococcal serotypes and total pneumococcal colonization density in young Peruvian children

  2023cites this paper
• Advances in immune response to pulmonary infection: Nonspecificity, specificity and memory

  2023cites this paper
• Using LASSO Regression to Estimate the Population-Level Impact of Pneumococcal Conjugate Vaccines

  2022cites this paper
• The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Otitis Media–Related Antibiotic Use Among Young Children in Tennessee, USA

  2022cites this paper
• Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis

  2022cites this paper
• Metabolomics of Respiratory Diseases.

  2022cites this paper
• Subunit-based vaccines

  2022cites this paper
• Disease Severity and Risk Factors of 30-Day Hospital Readmission in Pediatric Hospitalizations for Pneumonia

  2022cites this paper
• Prevalence of respiratory viruses in community-acquired pneumonia in children: a systematic review and meta-analysis.

  2022cites this paper
• Community-acquired pneumonia in hospitalised patients: changes in aetiology, clinical presentation, and severity outcomes in a 10-year period

  2022cites this paper
• Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt

  2022cites this paper
• Comparison of metagenomic next-generation sequencing using cell-free DNA and whole-cell DNA for the diagnoses of pulmonary infections

  2022cites this paper
• Public Health Value of a Hypothetical Pneumococcal Conjugate Vaccine (PCV) Introduction: A Case Study

  2022cites this paper
• Impact of Routine Childhood Immunization in Reducing Vaccine-Preventable Diseases in the US.

  2022cites this paper
• Sex-differences in incidence of hospitalizations and in hospital mortality of community-acquired pneumonia among children in Spain: a population-based study

  2022cites this paper
• Pathogen spectra in hospitalised and nonhospitalised children with community-acquired pneumonia

  2022cites this paper
• Trends in Illness Severity, Hospitalization, and Mortality for Community-Onset Pneumonia at 118 US Veterans Affairs Medical Centers

  2022cites this paper
• The hospitalization burden of all-cause pneumonia in China: A population-based study, 2009–2017

  2022cites this paper
• Childhood pneumonia in New Zealand

  2022cites this paper
• Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: A multi-center clinical microbiological study after PCV13 implementation.

  2022cites this paper
• Association of Pneumococcal Conjugate Vaccine Use With Hospitalized Pneumonia in Medicare Beneficiaries 65 Years or Older With and Without Medical Conditions, 2014 to 2017.

  2022cites this paper
• Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018

  2022cites this paper
• Pneumococcal capsule blocks protection by immunization with conserved surface proteins

  2021cites this paper
• Rapid diagnostic tests in the management of pneumonia

  2021cites this paper
• Burden of Invasive Pneumococcal Disease (IPD) During a 10-years Period in Bogotá, Colombia.

  2021cites this paper
• Disparities in Outcomes During Lower Respiratory Tract Infection in American Indian Children

  2021cites this paper
• Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age

  2021cites this paper
• The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland—A population-based time series analysis

  2021cites this paper
• Enfermedad por neumococo: desafíos actuales en los pacientes con enfermedad renal crónica y diabetes mellitus

  2021cites this paper
• Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe

  2021cites this paper
• Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India

  2021cites this paper
• Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges

  2021cites this paper
• Persistence of Pneumococcal Serotype 3 in Adult Pneumococcal Disease in Hong Kong

  2021cites this paper
• Particulate matter exposure predicts residence in high-risk areas for community acquired pneumonia among hospitalized children

  2021cites this paper
• Clinical risk, sociodemographic factors, and SARS-CoV-2 infection over time in Ontario, Canada

  2021cites this paper
• Antibiotic Prescribing Patterns for Hospitalized children with Community-Acquired Pneumonia in a Secondary Care Center.

  2021cites this paper
• Lower respiratory tract infection hospitalizations among American Indian/Alaska Native adults, Indian Health Service and Alaska Region, 1998-2014.

  2021cites this paper
• Pneumococcal capsule blocks protection by immunization with conserved surface proteins

  2021cites this paper
• Association of advanced age with intubation-related adverse events in the emergency department: a multicentre prospective observational study

  2021cites this paper
• Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China

  2021cites this paper
• Community-acquired pneumonia: Trends in and research on drug resistance and advances in new antibiotics.

  2021cites this paper
• Accuracy of Administrative Database Algorithms for Hospitalized Pneumonia in Adults: a Systematic Review

  2021cites this paper
• Pneumococcal Vaccination Mandates for Child Care: Impact of State Laws on Vaccination Coverage at 19-35 Months.

  2021cites this paper
• Global genomic pathogen surveillance to inform vaccine strategies: a decade-long expedition in pneumococcal genomics

  2021cites this paper
• Effectiveness of Pneumococcal Vaccination Against Hospitalized Pneumococcal Pneumonia in Older Adults: A Prospective, Test-Negative Study.

  2021cites this paper
• Diseases of the Respiratory Tract

  2021cites this paper
• A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant S. pneumoniae in Ambulatory and Hospitalized Adult Patients in the United States

  2021cites this paper
• Communicating Benefits from Vaccines Beyond Preventing Infectious Diseases

  2020cites this paper
• Influence of pneumococcal vaccination on the hospitalization of healthy pediatric patients due to typical community-acquired pneumonia.

  2020cites this paper
• Other Respiratory Viruses as a Cause of Community-Acquired Pneumonia

  2020cites this paper
• Emerging Resistance of Gram Negative Pathogens in Community-Acquired Pneumonia

  2020cites this paper
• Impact of 13-valent pneumococcal conjugate vaccine on the incidence of hospitalizations for all-cause pneumonia among children aged less than 5 years in Burkina Faso: an interrupted time-series analysis.

  2020cites this paper
• Destructive pneumonias in children

  2020cites this paper
• Effect of MRI on Surgical Approach and Outcomes in the Management of Subaxial Cervical Fractures.

  2020cites this paper
• Update in adult community-acquired pneumonia: key points from the new American Thoracic Society/Infectious Diseases Society of America 2019 guideline.

  2020cites this paper
• Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes

  2020cites this paper
• Inappropriate antibiotic prescriptions among pediatric inpatients in different type hospitals

  2020cites this paper
• A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

  2020cites this paper
• Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland.

  2020cites this paper
• The Prevention of Infections in Older Adults: Vaccination

  2020cites this paper
• Outcome of Severe Bacterial Pneumonia in the Era of Pneumococcal Vaccination

  2020cites this paper
• Respiratory syncytial virus and airway microbiota – A complex interplay and its reflection on morbidity

  2020cites this paper
• Consensus document on community-acquired pneumonia in children. SENP-SEPAR-SEIP

  2020cites this paper
• Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines.

  2020cites this paper
• Advances in community-acquired pneumonia

  2020cites this paper
• Hospitalisations due to respiratory syncytial virus infection in children with Down syndrome before and after palivizumab recommendation in Japan

  2020cites this paper
• Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence

  2020cites this paper
• Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency

  2020cites this paper
• Indolent Presentations of Leukemic Lung Disease in Acute Myeloid Leukemia

  2020cites this paper
• Necrotizing pneumonia among Italian children in the pneumococcal conjugate vaccine era

  2020cites this paper
• Pneumonia Hospitalization Coding Changes Associated With Transition From the 9th to 10th Revision of International Classification of Diseases.

  2020cites this paper